AUROBINDO

Date: 02.04.2020

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, BandraKurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** PhirozJeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir,

Sub: Press Release on mutual termination of definitive agreement entered into for acquisition of certain commercial operations of Sandoz – Reg.,

Further to our letter dated September 6, 2018, we enclose a copy of the Press Release that is being issued by the Company on mutual termination of definitive agreement entered into for acquisition of commercial operations and three manufacturing facilities in USA from Sandoz Inc., USA, a Novartis Division by our wholly owned subsidiary, Aurobindo Pharma USA Inc., USA since approval from the U.S. Federal Trade Commission for the transaction was not obtained within anticipated timelines.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Encl.: Press Release

NEWS RELEASE
2nd April 2020, Hyderabad, India

Mutual termination of agreement entered with Sandoz Inc for acquisition of US generic oral solids and dermatology businesses

Aurobindo today announced the mutual agreement with Sandoz Inc to terminate the agreement to buy the Sandoz US generic oral solids and dermatology businesses from Sandoz Inc. This decision was taken as approval from the U.S. Federal Trade Commission for the transaction was not obtained within anticipated timelines.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

For further information, please contact:

Investor Relations
Phone: 040-66725401 / 66725000
Mobile: +91 98486 67906
Email: ir@aurobindo.com

Disclaimer:

This press release contain statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information.